New combo therapy aims to shrink rectal tumors and save sphincters

NCT ID NCT06493240

Completed Disease control Sponsor: Peking University People's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested whether adding a PD-1 inhibitor (Sintilimab) after standard chemoradiotherapy could improve outcomes for 30 patients with locally advanced mid-low rectal cancer. Participants received radiation and chemotherapy, then three doses of Sintilimab, followed by surgery. The study measured how many patients had a complete tumor disappearance and how many could keep their anal sphincter.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sintilimab (PD-1 inhibitor) combined with capecitabine-based chemoradiotherapy
What this could lead to: If successful, this combination could increase the chance of eliminating the tumor before surgery and help more patients avoid permanent colostomy.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply broadly. Immune-related side effects from the PD-1 inhibitor are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rectal cancer rectum adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED RECTAL CANCER

Contacts and locations

Locations

Peking University People's Hospital

Beijing, Beijing Municipality, 100044, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.